The Erythropoietin Stimulating Agents market is valued at approximately USD 8,223 million in 2020 and is expected to witness a revenue of USD 13,436 million in 2026, with a CAGR of 8.6% over the forecast period.
According to the research study published in the American Journal of Kidney Disease, 2020, in the patients with COVID-19, with or without Acute Kidney Injury(AKI) and anemia, Erythropoiesis Stimulating agents (ESAs) should be avoided in the therapy, as these patients are unlikely to mount an effective response to ESAs due to the inflammation. Thus, the risks associated with ESA treatments are expected to outweigh the potential benefits. Hence, the COVID-19 pandemic is expected to severely impact the studied market growth during the pandemic.
The Erythropoietin Stimulating Agents market is driven by an increasing number of patients suffering from anemia, increasing applications in HIV infections, end-stage renal disorder, along with risks of thrombosis, during surgeries, and pure red cell aplasia.
Anemia has been one of the serious diseases related to nutrition over the past few decades and is the major reason for increased morbidity and mortality, especially in low and middle-income countries. According to a research article published in PLoS One, 2019, Anemia is estimated to affect nearly 1.62 billion people worldwide and the prevalence of anemia was found to be 41.1% in Ethiopia. Additionally, as per the Lancet Global Health, 2019, India is estimated to account for nearly one-quarter of the global anemia cases. Iron Deficiency Anemia is common in children and women and is associated with sensory, motor, cognitive, language, and socioemotional deficits. Hence, the early detection and initiation of effective treatment strategies in the early stage of anemia are very important, especially among infants.
Other causes of anemia include parasite infections, such as Ascaris, schistosomiasis, and hookworms, which can lower the hemoglobin (Hb) concentration in blood, along with heavy blood loss during menstruation in women.
Additionally, as per the Centers for Disease Control and Prevention (CDC) 2019 report, it is estimated that about 37 million (15%) adult population in the United States had chronic kidney disease (CKD), which increases the severity of anemia. Therefore, as the number of people affected by anemia increases, the demand for erythropoietin stimulating agents also increases, which aid in stimulating the production of more red blood cells. Hence, the aforementioned factors are expected to boost market growth over the forecast period. However, stringent regulatory guidelines to obtain the product approvals and the adverse side effects of Erythropoietin stimulating agents are expected to hamper the market growth.
Key Market Trends
Cancer Application Expected to Dominate the Market Over the Forecast Period
Anemia is observed in the majority of patients undergoing cancer treatment, which is expected to drive the studied segment growth over the forecast period. The severity of the disease in patients depends on the type of chemotherapy used, type and stage of neoplasia, and patient characteristics. Severe Anemia, particularly in children and the elderly population can lead to fatigue, weakness, and depression, which severely reduces the quality of life of cancer patients.
Besides, anemia impairs the efficacy of cancer therapies. Several research studies and clinical trials have revealed that treating anemia that is associated with various cancers with erythropoietin can improve the clinical outcome of these patients. Erythropoietin acts against two main causes of anemia in cancer patients undergoing chemotherapy, i.e., against myelosuppression and endogenous erythropoietin deficiency. Patients diagnosed with anemia associated with cancers are most likely to be prescribed with erythropoietin in the form of epoetin alfa and epoetin beta. The most prescribed products include Procrit, Epogen, and NeoRecormon.
As per the research article published in the Lancet, 2020, there was no direct co-relation found to state that the cancer patients on cytotoxic chemotherapy or other anticancer treatment possess higher chances of mortality from COVID-19 disease as compared with those not on active treatment. Hence, COVID-19 is expected to not impact the mortality rate of cancer patients on chemotherapy, which in turn may not impair the segment growth during the pandemic. However, due to the temporary postponement of elective surgeries during COVID-19, the cancer treatments are reduced to some extent.
As per Globocan 2020, the incidence of new cancer cases was estimated to be 19,292,789 in 2020, with nearly 9,958,133 deaths due to cancers globally. Additionally, the new cancer incidence is estimated to reach 30.2 million by 2040 as per International Agency for Research on Cancer(IARC) worldwide. As the rapidly dividing cancer cells consume a large amount of iron for their DNA replication, growth, and metastatic process, cancer patients are always diagnosed with severe anemia. Hence, with the increase in cancer patients and the rise in chemotherapy procedures, the erythropoietin stimulating agents market is expected to grow during the forecast period.
North America is Expected to Hold the Largest Market Share over the Forecast Period
The market for erythropoietin stimulating agents in North America is estimated to hold the largest share on account of the high occurrence of various disorders that eventually cause anemia in the region.
According to the American Society of Hematology, 2020, patients receiving active treatment for Aplastic Anemia may experience immunosuppression, which increases the risk for infection with COVID-19 and associated complications during the pandemic. Additionally, Hospitalization of patients for anti-thymocyte globulin (ATG) administration for Aplastic Anemia treatment may be problematic given lack of bed availability and risk of exposure to COVID-19 patients. Hence, the pandemic situation is expected to impact the treatment procedures for anemia, which in turn affects the studied market growth.
Erythropoietin stimulating agents have been effectively used in the treatments for various chronic diseases, like chronic kidney disease (CKD), cancer, neural, and HIV infections. Adults with diabetes or higher blood pressure are prone to CKD. According to the Centers for Disease Control and Prevention(CDC), the National Diabetes Statistics Report, 2020, 34.2 million people of all ages, accounting for 10.5% of the American population had diabetes in 2018. Hence with the increasing number of people at high risk for CKD, the market for erythropoietin stimulating agents is expected to accelerate the market growth.
In the North American region, the United States holds the largest market share. According to the GLOBOCON 2020, the new cancer cases diagnosed were 2,281,658 in the United States in 2020, with 612,390 deaths. Among all cancers, breast cancer had the highest incidence with 253,465 cases, followed by lung (227,875), Prostate(209,512), and colon(101,809) new cancer cases in 2020 in the United States. The high incidence of cancers leads to the demand for Erythropoietin stimulating agents, to minimize anemic conditions in target patients, which in turn is expected to boost the market growth in the region over the forecast period.
The erythropoietin stimulating agents market is highly competitive, and it includes global and local companies. Some of the key players in the market are Amgen, Thermo Fisher Scientific, Johnson and Johnson, F. Hoffmann La Roche, and Pfizer Inc. Numerous pharmaceutical manufacturers are taking initiatives to develop and produce erythropoietin stimulating agents (ESAs) after the expiration of patents and are also evolving various strategic alliances such as acquisitions and collaborations to expand the product portfolio globally.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support